Gastrointestinal Cancer

Marwan Fakih, MD, professor, Department of Medical Oncology and Therapeutics Research, associate director for Clinical Investigations, Comprehensive Cancer Center, medical director, Judy and Bernard Briskin Center for Clinical Research, co-director, Gastrointestinal Cancer Program, and section head, Gastrointestinal Medical Oncology, City of Hope, discusses future directions in metastatic colorectal cancer (mCRC).

Three months of adjuvant oxaliplatin-based therapy in patients with high-risk, stage II colorectal cancer was found to be inferior to 6 months of treatment.

Gulam A. Manji, MD, PhD, discusses the difference between right- and left-sided tumors in colorectal cancer and the appropriate treatment for right-sided tumors based on a subgroup analysis.

S. Lindsey Davis, MD, an assistant professor of medicine and gastrointestinal medical oncologist at the University of Colorado Cancer Center, discusses an investigational immunotherapy combination being explored in patients with HER2-positive gastric and gastroesophageal junction (GEJ) cancer.

David J. Pinato, MD, PhD, clinical senior lecturer in medical oncology, clinician scientist, consultant medical oncologist, Department of Surgery and Cancer, Imperial College London, discusses the molecular makeup of the tumor microenvironment in neuroendocrine malignancies.

Heinz-Josef Lenz, MD, FACP, discusses the safety profile of nivolumab plus ipilimumab in the phase II CheckMate-142 trial for treatment-naïve patients with microsatellite instability–high/mismatch repair deficient colorectal cancer.

The Japanese Ministry of Health, Labour and Welfare has approved TAS-102 (trifluridine/tipiracil; Lonsurf) for the treatment of patients with unresectable advanced or recurrent gastric cancer that has progressed after chemotherapy.

The frontline combination of nivolumab (Opdivo) and ipilimumab (Yervoy) showed a robust and durable clinical benefit in patients with metastatic colorectal cancer.

Philip A. Philip, MD, PhD, FRCP, professor of medicine, Wayne State University School of Medicine, clinical professor of oncology at Barbara Ann Karmanos Cancer Institute, discusses adverse events (AEs) associated with Lutathera (lutetium Lu 177 dotatate) in neuroendocrine tumors (NETs).

Shota Fukuoka, MD, PhD, discusses the results of the study evaluating regorafenib and nivolumab in patients with previously treated gastric and colorectal cancers.

Byrne Lee, MD, chief, Upper GI and Mixed Tumor Surgery Service, associate clinical professor of surgical oncology, Department of Surgery, and surgical oncologist, City of Hope, discusses data regarding the use of hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with metastatic colorectal cancer (mCRC).

S. Lindsey Davis, MD, an assistant professor of medicine and gastrointestinal medical oncologist at the University of Colorado Cancer Center, discusses the role of ramucirumab (Cyramza) in the treatment of patients with gastric/gastroesophageal junction (GEJ) adenocarcinoma.

Pashtoon M. Kasi, MBBS, MD, MS, discusses the use of ctDNA testing throughout treatment for patients with colorectal cancer and ongoing research on liquid biopsies.

Gulam A. Manji, MD, PhD, discusses clinical trials for patients with colorectal cancer harboring BRAF or other molecular abnormalities.

Jonathan Mizrahi, MD, a hematology/oncology fellow at The University of Texas MD Anderson Cancer Center, discusses encouraging trial findings in metastatic colorectal cancer (mCRC).

Tim Iveson, MD, FACP, discusses the International Duration Evaluation of Adjuvant Chemotherapy Collaboration, which examines the effects of adjuvant oxaliplatin-based therapy given for 3 months versus 6 months in patients with high-risk stage II colorectal cancer.

Ripretinib (DCC-2618) improved progression-free survival compared with placebo in patients with fourth-line and fourth-line plus advanced gastrointestinal stromal tumors, according to topline findings of the phase III INVICTUS study (NCT03353753).

Vaibhav Sahai, MBBS, assistant professor of medicine at the University of Michigan, discusses sequencing strategies in metastatic pancreatic cancer.

Anthony B. El-Khoueiry, MD, associate professor of clinical medicine, Keck School of Medicine, USC Norris Comprehensive Cancer Center, discusses research on biomarkers in hepatocellular carcinoma (HCC).